New Study Demonstrates that SL-NAD+ delivers NAD+ into Cells

Contributed by: PR Newswire

Tags

iX-Biopharma-UK

More Like This

ACCESS Newswire associated0

GEN and Sulfateq BV Announce Positive Phase 1 Trial Data on Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

PR Newswire associated0

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

PR Newswire associated0

Novadip Biosciences SA announces significant clinical milestones for both of its clinical-stage programs

PR Newswire associated0

Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024

New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD

Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned